// App-Quantinova.ai

TPS368 : MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Laurence Albiges

  • Li Fan

  • Rodolfo F. Perini

  • Donna Vickery

  • Thomas Powles

  • Brian I. Rini

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Gustave Roussy, Villejuif, France

  • Merck & Co., Inc., Kenilworth, NJ

  • Bart's Cancer Institute, London, United Kingdom

  • Vanderbilt University Medical Center, Nashville, TN

Locations

  • United States

  • France

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Neoplastic meningitis

  • Renal cell carcinoma

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Serine/threonine-protein kinase mTOR

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02974738

  • NCT04195750

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved